Saturday, March 15, 2025 | 10:30 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Natco Pharma Q3 net down 26% to Rs 159 cr on flat revenue, fall in margins

Margin reduction of Oseltamivir in the US market cited as the major cause for the decline in profits during the quarter

Profit and loss
Premium

Photo: Shutterstock

BS Reporter Hyderabad
Hyderabad-based Natco Pharma Limited has reported a 26.72 per cent decline in consolidated net profit to Rs 159.3 crore for the quarter ended December 2018, owing to flattish revenues and fall in margins. 
 
The company's consolidated revenues grew by little over one per cent to Rs 580 crore for the quarter under review, as compared to Rs 573.6 crore for the same quarter in the previous financial year and marginally lower on a sequential basis. However, the total expenditure rose 26 per cent to Rs 375.3 crore, from Rs 297.2 crore in the year-ago period.

ALSO READ: 

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in